Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

@article{Gaber1998ResultsOT,
  title={Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.},
  author={A Osama Gaber and M. Roy First and Raymond J Tesi and Robert S. Gaston and Robert Mendez and Laura L. Mulloy and Jimmy A Light and Lillian W. Gaber and Elizabeth Squiers and Rodney J. Taylor and John F. Neylan and R. W. Prasaad Steiner and Stuart J Knechtle and Douglas J. Norman and Fuad S. Shihab and Giacomo Basadonna and Daniel C. Brennan and Ernest E Hodge and Barry D. Kahan and Lawrence Kahan and Steven Steinberg and E. Steve Woodle and Laurence K. Chan and John Marshall Ham and Timothy J. Schroeder},
  journal={Transplantation},
  year={1998},
  volume={66 1},
  pages={29-37}
}
BACKGROUND Thymoglobulin, a rabbit anti-human thymocyte globulin, was compared with Atgam, a horse anti-human thymocyte globulin for the treatment of acute rejection after renal transplantation. METHODS A multicenter, double-blind, randomized trial with enrollment stratification based on standardized histology (Banff grading) was conducted. Subjects… CONTINUE READING